USITC publishes HTS 2026 Revision 20 #
The US International Trade Commission published Revision 20 of the 2026 Harmonized Tariff Schedule on September 28, 2026. It carries Commerce's September 23 notice on the Section 232 pharmaceutical duties: U.S. note 40 is rewritten and a new heading, 9903.04.70, exempts pharmaceuticals used solely for clinical trials and research. No Column 1 rate changed.
- Effective
- In force from September 29, 2026
- Countries of origin
- all
- Chapter 99 headings
- 9903.04.70
The change record lists U.S. note 40(a), 40(c), 40(c)(i), 40(c)(iii) and 40(i) as modified and heading 9903.04.70 as established, all effective September 29, 2026, under the Commerce notice published in the Federal Register on September 23, 2026 (91 FR 60360).
The list of covered tariff lines in note 40(c) is corrected to current 10-digit statistical numbers and now names 149 lines in Chapters 29 and 30. Inactive ingredients and excipients are no longer pharmaceutical articles, and unpatented animal-health products count as generics.
New heading 9903.04.70 carries no additional duty for pharmaceutical articles and associated ingredients used solely for clinical trials, research and development, or other non-commercial applications.
No Chapter 1 to 97 line was added, removed or re-rated, so classifications and Column 1 rates filed against Revision 19 still stand. The Airlift tariff simulator loaded Revision 20 on October 6, 2026.
What importers should do
- If you import drug ingredients or finished medicines, check each 10-digit line against the corrected note 40(c) list; some lines moved to new statistical numbers.
- For clinical-trial or research shipments, ask your broker to file under 9903.04.70 and keep the documents that show the non-commercial use.